Regulatory Focus™ > News Articles > 4 > Recon: Trump Tariffs Target China-Made Drug Ingredients

Recon: Trump Tariffs Target China-Made Drug Ingredients

Posted 04 April 2018 | By Ana Mulero 

Recon: Trump Tariffs Target China-Made Drug Ingredients

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

In Focus: US In Focus: International 
  • Sofinnova raises €275M crossover fund to back late-stage firms (Fierce) (Endpoints)
  • Kymera pens new pact with GSK as protein degradation R&D continues to ramp up (Fierce) (The Pharma Letter)
  • Exclusive - Hospital contract disarray highlights challenges to Saudi healthcare reform (Reuters)
  • To be a global player, China plays by global standards (The Pharma Letter-$)
  • US may revoke special tariff if India continues pricing control on medical devices (Economic Times)
Pharmaceuticals & Biotechnology
  • Benefit of GenSight's gene therapy not so clear (BioPharma Dive) (Endpoints)
  • Déjà vu? PhRMA rolls drug cost ads, insurers push back—this time on costly coupon rules (Fierce)
  • How long are delays in cancer drug approvals outside the U.S.? (Drug Channels)
  • Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks (Fierce)
  • Celgene, AbbVie extracted higher prices in Q4 as other pharmas netted less: report (Fierce)
  • Agilent pays $105 million to acquire DNA firm Lasergen (The Pharma Letter-$) (Press)
  • Volatility returns for big biopharma (EP Vantage
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • Genomic analysis uncovers prevalence of RNA splicing mutations in 33 tumor types (Fierce)
  • NIH launches HEAL Initiative, doubles funding to accelerate scientific solutions to stem national opioid epidemic (NIH)
  • How CRISPR works, explained in two minutes (STAT)
  • Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors (Press)
  • Cancer researchers push to relax rules for clinical trials (Nature)
  • Allergan notches third trial success for depression drug (BioPharma Dive)
Medical Devices
  • CVS Health eyes kidney patients for next expansion into care (ABC News)
  • MIT Ends Contract With Nectome, the 100% Fatal Brain Freeze Startup (Fortune)
  • Genomics Is on the Rise (MedPage Today)
  • Siemens wins FDA nod for Somatom Edge plus CT scanner (MassDevice)
  • Curetis wins FDA nod for respiratory infection diagnostic system (Drug Delivery Business News)
  • Boomers line up for joint replacements, and their expectations are high (STAT-$)
  • Nvidia's Project Clara Medical Imaging Supercomputer Will Speed Up Detection Of Deadly Diseases (Forbes)
US: Assorted & Government
  • Planned Parenthood President Cecile Richards: Jared Kushner and Ivanka Trump offered a 'bribe' to stop abortions (CNBC)
  • Amazon could do a lot to fix the U.S. health-care system — but Walmart could do more (CNBC)
  • Taxpayers bore the brunt of Trump’s ACA changes (Axios)
  • The politics of ACA rate hikes will be 2016 in reverse (Axios)
  • How Studying Sewage May Help Slow the Opioid Epidemic (Fortune)
  • U.S. Obamacare 2018 exchange enrollment drops 3 percent: CMS (Reuters)
  • Lab animal regulations can be simplified without weakening welfare standards (STAT)
  • Why Private Equity Loves Retail Healthcare (Forbes)
Upcoming Meetings & Events Europe
  • BiondVax preps for phase 3 universal flu vaccine trial in Europe (Fierce)
  • MA granted for drug tested in just 34 patients (The Pharma Letter-$)
  • Russia to start exports of innovative polio vaccine (The Pharma Letter-$)
  • Collaboration formed for development of novel IgE antibodies (EPM Magazine)
  • Field Safety Notice - 26 to 30 March 2018 (MHRA)
  • Abiomed wins CE Mark for Impella 5.5 (MassDevice) (Press)
  • EPO fee reduction takes effect as of 1 April 2018 (EPO)
  • Prioritise universal health coverage, healthier populations create more productive economies: WHO (Business Standard)
  • Curetis’ Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority (Press)
  • SARS-like outbreak among pigs rekindles concerns virus could again strike humans (STAT-$)
  • South Korea has a sting in the tail for drinkers who mix wasps and soju (Channel NewsAsia)
  • Glenmark gets license to market Akynzeo in India (The Pharma Letter-$)
  • India waking up to a malnutrition crisis and its dire consequences (Qrius)
  • CDSCO move to choose notified bodies for medical devices hits wall as low fee structure drives away firms (pharmabiz)
Australia Canada
  • B.C. targets private health care with new penalties for extra billing (The Globe and Mail)
  • Glycovax Pharma Files a Patent Application for a New Semi-Synthetic Vaccine against Breast Cancers (Press)
  • Drug company knew Oxycontin was addictive and lied about it, says plaintiff in class action suit (CBC News)
General Health & Other Interesting Articles Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.

Need to contact the editor of Regulatory Reconnaissance? Email us at

A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Categories: Recon

Regulatory Focus newsletters

All the biggest regulatory news and happenings.